Incretin-based therapy for type 2 diabetes: A real class effect?

Int J Cardiol. 2017 Jan 15:227:141-142. doi: 10.1016/j.ijcard.2016.11.018. Epub 2016 Nov 9.

Authors

Gianluigi Savarese¹, Lars H Lund¹, Giuseppe M C Rosano²

Affiliations

¹ Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
² Cardiovascular and Cell Sciences Research Institute, St George's University, London, UK; IRCCS San Raffaele Pisana, Rome, Italy. Electronic address: grosano@sgulac.uk.

PMID: 27866064
DOI: 10.1016/j.ijcard.2016.11.018

No abstract available

Publication types

Meta-Analysis
Review

MeSH terms

Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / drug therapy
Cardiovascular Diseases / epidemiology*
Comorbidity
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology*
Female
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use*
Incretins / adverse effects
Incretins / therapeutic use*
Male
Prognosis
Randomized Controlled Trials as Topic
Risk Assessment
Survival Rate
Treatment Outcome

Substances

Hypoglycemic Agents
Incretins